专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080194655A1 ZERO ORDER CONTROLLED RELEASE COMPOSITIONS OF TIZANIDINE 审中-公开
标题翻译：零售控制释放组合物
公开(公告)号：US20080194655A1
公开(公告)日：2008-08-14
申请号：US12015575
申请日：2008-01-17
申请人： Scott Bull , Suneel Gupta , Rhea Donley , Nishit Modi , Noymi Yam
发明人： Scott Bull , Suneel Gupta , Rhea Donley , Nishit Modi , Noymi Yam
IPC分类号： A61K31/433
CPC分类号： A61K31/433 , A61K9/0004 , A61K9/2086
摘要： The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.
摘要翻译：本发明涉及替扎尼定的新型控释制剂。本发明还提供使用替扎尼定的新型控制释放制剂治疗患者的方法。

2. 发明授权

US08524749B2 Controlled release compositions of tizanidine 有权
标题翻译：替扎尼定的控释药组合物
公开(公告)号：US08524749B2
公开(公告)日：2013-09-03
申请号：US12014980
申请日：2008-01-16
申请人： Scott Bull , Suneel Gupta , Rhea Donley , Nishit Modi , Noymi Yam
发明人： Scott Bull , Suneel Gupta , Rhea Donley , Nishit Modi , Noymi Yam
IPC分类号： A61K31/433 , A61P21/00
CPC分类号： A61K31/433
摘要： The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.
摘要翻译：本发明涉及替扎尼定的新型控释制剂。本发明还提供使用替扎尼定的新型控制释放制剂治疗患者的方法。

3. 发明申请

US20080214629A1 CONTROLLED RELEASE COMPOSITIONS OF TIZANIDINE 有权
标题翻译： TIZANIDINE的控制释放组合物
公开(公告)号：US20080214629A1
公开(公告)日：2008-09-04
申请号：US12014980
申请日：2008-01-16
申请人： Scott Bull , Suneel Gupta , Rhea Donley , Nishit Modi , Noymi Yam
发明人： Scott Bull , Suneel Gupta , Rhea Donley , Nishit Modi , Noymi Yam
IPC分类号： A61K31/433 , A61P21/00
CPC分类号： A61K31/433
摘要： The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.
摘要翻译：本发明涉及替扎尼定的新型控释制剂。本发明还提供使用替扎尼定的新型控制释放制剂治疗患者的方法。

4. 发明申请

US20050260268A1 Methods and dosage forms for controlled delivery of alprazolam 审中-公开
标题翻译：控制递送阿普唑仑的方法和剂型
公开(公告)号：US20050260268A1
公开(公告)日：2005-11-24
申请号：US10949900
申请日：2004-09-24
申请人： Nishit Modi , Suneel Gupta , Nipun Davar , Sonya Seroff
发明人： Nishit Modi , Suneel Gupta , Nipun Davar , Sonya Seroff
IPC分类号： A61K9/00 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/36 , A61K31/5517
CPC分类号： A61K31/5517 , A61K9/0004 , A61K9/2086
摘要： A dosage form for delivery of alprazolam is described. The sustained release dosage form provides via once-a-day dosing a therapeutically effective average steady-state plasma alprazolam concentration, where the maximum attained plasma concentration is achieved more than about 14 hours after administration. The slow, sustained release reduces side effects such as sedation and abuse potential.
摘要翻译：描述了用于递送阿普唑仑的剂型。持续释放剂型通过每天一次给药治疗有效的平均稳态血浆阿普唑仑浓度，其中在给药后超过约14小时达到最大达到的血浆浓度。缓慢持续释放可减少诸如镇静和滥用潜力的副作用。

5. 发明申请

US20050069587A1 Novel drug compositions and dosage forms of topiramate 审中-公开
标题翻译：托吡酯的新型药物组合物和剂型
公开(公告)号：US20050069587A1
公开(公告)日：2005-03-31
申请号：US10930917
申请日：2004-08-31
申请人： Nishit Modi , Suneel Gupta
发明人： Nishit Modi , Suneel Gupta
IPC分类号： A61K9/00 , A61K31/35 , A61K31/7048 , A61K9/48 , A61K9/24
CPC分类号： A61K31/7048 , A61K9/0004 , A61K31/35
摘要： The present invention is directed to novel drug compositions and dosage forms comprising said drug compositions. The drug compositions of the present invention comprise a pharmaceutical agent and a solubilizing agent. The drug compositions of the present invention are particularly advantageous for use with low solubility and/or low dissolution rate pharmaceutical agents. The present invention is further directed to methods for manufacturing of said drug compositions and dosage forms. The present invention is further directed to methods of treatment comprising administration of said drug compositions and dosage forms. The present invention further provides topiramate drug compositions, dosage forms and methods of treatment which provide a reduction in the frequency and/or severity of at least one adverse event associated with topiramate treatment.
摘要翻译：本发明涉及包含所述药物组合物的新型药物组合物和剂型。本发明的药物组合物包含药剂和增溶剂。本发明的药物组合物特别适用于低溶解度和/或低溶解速率的药剂。本发明还涉及制备所述药物组合物和剂型的方法。本发明进一步涉及包括施用所述药物组合物和剂型的治疗方法。本发明还提供了与托吡酯治疗相关的至少一种不良事件的频率和/或严重性降低的托吡酯药物组合物，剂型和治疗方法。

6. 发明授权

US5851989A Method of extending the plasma half-life of vascular endothelial cell growth factor 失效
标题翻译：延长血管内皮细胞生长因子血浆半衰期的方法
公开(公告)号：US5851989A
公开(公告)日：1998-12-22
申请号：US465895
申请日：1995-06-06
申请人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
发明人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
IPC分类号： A61K38/22 , A61K9/00 , A61K31/715 , A61K38/17 , A61K38/18 , A61K47/36 , A61P1/16
CPC分类号： A61K9/0019 , A61K31/721 , A61K31/727 , A61K38/178 , A61K45/06 , A61K47/36
摘要： The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of cells. In one embodiment of the invention, the heparin-binding protein is a growth factor or selectin. The binding inhibitory compound can, for example, be a purified native heparin preparation, a heparin fragment, or another polyanionic compound, such as dextran sulfate, heparan sulfate, pentosan sulfate, or hyaluronate.
摘要翻译：本发明提供了一种延长肝素结合蛋白的血浆半衰期的方法，其通过用能够抑制它们与细胞表面上的低亲和力肝素结合位点的结合的治疗上可接受的化合物共同掺入这种蛋白质。在本发明的一个实施方案中，肝素结合蛋白是生长因子或选择蛋白。结合抑制性化合物可以是例如纯化的天然肝素制剂，肝素片段或另一种聚阴离子化合物，例如硫酸葡聚糖，硫酸乙酰肝素，戊糖硫酸盐或透明质酸盐。

7. 发明申请

US20050106249A1 Once-a-day, oral, controlled-release, oxycodone dosage forms 审中-公开
标题翻译：每日一次，口服，控释，羟考酮剂型
公开(公告)号：US20050106249A1
公开(公告)日：2005-05-19
申请号：US10977403
申请日：2004-10-28
申请人： Stephen Hwang , Nishit Modi , Padmaja Shivanand
发明人： Stephen Hwang , Nishit Modi , Padmaja Shivanand
IPC分类号： A61K9/00 , A61K31/485 , A61K9/26
CPC分类号： A61K31/485 , A61K9/0004 , A61K2300/00
摘要： Oxycodone formulations are provided which produce substantially flat in vivo steady state plasma profiles. Tolerance levels associated with such profiles and tolerance levels associated with biphasic profiles are shown not to be statistically different. The substantially flat in vivo steady state plasma profiles are produced by dosage forms having substantially zero order in vitro release profiles. Such release profiles produce low single dose in vivo Cmax levels which can reduce the probability of adverse side effects.
摘要翻译：提供氧可酮制剂，其产生基本上平坦的体内稳态血浆曲线。与双相曲线相关的这种轮廓和公差水平相关联的公差水平显示为不具有统计学差异。基本上平坦的体内稳态血浆曲线通过具有基本上为零次的体外释放曲线的剂型产生。这种释放曲线产生较低的单剂量体内C max水平，这可以降低不良副作用的可能性。

8. 发明授权

US5464815A Inhibition of heparin-binding 失效
标题翻译：抑制肝素结合
公开(公告)号：US5464815A
公开(公告)日：1995-11-07
申请号：US254390
申请日：1994-06-06
申请人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
发明人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
IPC分类号： A61K38/22 , A61K9/00 , A61K31/715 , A61K38/17 , A61K38/18 , A61K47/36 , A61P1/16 , C07K1/14 , G01N33/68
CPC分类号： A61K9/0019 , A61K31/721 , A61K31/727 , A61K38/178 , A61K45/06 , A61K47/36
摘要： The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of cells. In one embodiment of the invention, the-heparin-binding protein is a selectin. The binding inhibitory compound can, for example, be a purified native heparin preparation, a heparin fragment, or another polyanionic compound, such as dextran sulfate, heparan sulfate, pentosan sulfate, or hyaluronate.
摘要翻译：本发明提供了一种延长肝素结合蛋白的血浆半衰期的方法，其通过用能够抑制它们与细胞表面上的低亲和力肝素结合位点的结合的治疗上可接受的化合物共同掺入这种蛋白质。在本发明的一个实施方案中，肝素结合蛋白是选择蛋白。结合抑制化合物可以是例如纯化的天然肝素制剂，肝素片段或另一种聚阴离子化合物，例如硫酸葡聚糖，硫酸乙酰肝素，戊糖硫酸酯或透明质酸盐。

9. 发明授权

US5849689A Method of extending the plasma half-life of deletion variants of hepatocyte growth factor 失效
标题翻译：延长肝细胞生长因子缺失变体血浆半衰期的方法
公开(公告)号：US5849689A
公开(公告)日：1998-12-15
申请号：US466326
申请日：1995-06-06
申请人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
发明人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
IPC分类号： A61K38/22 , A61K9/00 , A61K31/715 , A61K38/17 , A61K38/18 , A61K47/36 , A61P1/16
CPC分类号： A61K9/0019 , A61K31/721 , A61K31/727 , A61K38/178 , A61K45/06 , A61K47/36
摘要： The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of the cells. In one embodiment of the invention, the heparin-binding protein is a growth factor. The binding inhibitory compound can, for example, be a purified native heparin preparation, a heparin fragment, or another polyanionic compound, such as dextran sulfate, heparan sulfate, pentosan sulfate, or hyaluronate.
摘要翻译：本发明提供了一种延长肝素结合蛋白的血浆半衰期的方法，其通过用能够抑制它们与细胞表面上的低亲和力肝素结合位点的结合的治疗上可接受的化合物共同掺入这种蛋白质。在本发明的一个实施方案中，肝素结合蛋白是生长因子。结合抑制性化合物可以是例如纯化的天然肝素制剂，肝素片段或另一种聚阴离子化合物，例如硫酸葡聚糖，硫酸乙酰肝素，戊糖硫酸盐或透明质酸盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式